<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104005">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01656161</url>
  </required_header>
  <id_info>
    <org_study_id>Debio 8206-SC-301</org_study_id>
    <secondary_id>KRA75538</secondary_id>
    <nct_id>NCT01656161</nct_id>
  </id_info>
  <brief_title>Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer</brief_title>
  <official_title>A Multicentre, Open, Non-comparative, Phase III Study on the Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 22.5 mg 6-month Formulation in Patients With Advanced Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Debiopharm International SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quintiles</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Debiopharm International SA</source>
  <oversight_info>
    <authority>South Africa: Medicines Control Council</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will investigate the efficacy, pharmacokinetics and safety of triptorelin embonate
      22.5 mg 6-month formulation administered by subcutaneous injections in patients with
      prostate cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will investigate the efficacy, pharmacokinetics and safety of two subcutaneous
      injections of triptorelin embonate 22.5 mg 6-month formulation in patients with prostate
      cancer. The total duration of the study per patient will be 12 months (48 weeks)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Primary Efficacy</measure>
    <time_frame>Month 1 (Day 29) and from Month 2 (Day 57) to end of Month 12 (Day 337)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of patients achieving castrate levels of serum testosterone (&lt; 1.735 nmol/L) by Day 29.
Percentage of patients maintaining castrate levels of serum testosterone (&lt; 1.735 nmol/L) from Month 2 (Day 57) to end of Month 12 (Day 337).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary efficacy</measure>
    <time_frame>Day 1 to Day 337</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Secondary Efficacy
Proportion of patients showing ≤ 1.0 IU/L increase in serum LH from 0 hour to 2 hours post-injection of first and second IMP injection.
Percentage changes in PSA from baseline throughout treatment.
Percentage of patients who show testosterone levels ≥ 1.735 nmol/L after the second injection (AOC).
PK/PD (subset of 15 patients)
Testosterone PD metrics in subset of 15 patients: AUC1-169d, Cmax, tmax, tcast.
Triptorelin PK metrics in subset of 15 patients (for both injection periods): AUC1-169d, AUC169-337d, Cmax, tmax.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Triptorelin embonate 22.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two consecutive injections of triptorelin pamoate 22.5 mg at an interval of 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin embonate 22.5 mg</intervention_name>
    <description>Two consecutive injections of triptorelin pamoate 22.5 mg at an interval of 24 weeks</description>
    <arm_group_label>Triptorelin embonate 22.5 mg</arm_group_label>
    <other_name>Pamorelin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically proven prostate cancer.

          -  Prostate cancer stage T3-4NxMx, TxN1Mx or TxNxM1 according to the TNM classification
             (see Appendix A: TNM Classification) or the patient should have rising PSA after
             failed local therapy and be candidate for androgen deprivation therapy.

          -  Serum testosterone levels &gt; 5 nmol/L.

          -  Karnofsky performance index &gt; 40 (see Appendix B: Karnofsky Performance Scale).

          -  Expected survival &gt; 18 months.

          -  Absence of another malignancy, other than local dermatological, for the previous 5
             years.

          -  Signed informed consent before entry into the study.

        Exclusion Criteria:

          -  Prior hormonal treatment for prostate cancer within 6 months prior to study start.

          -  Use of finasteride (Proscar®) or dutasteride (Avodart®/Avolve®) within 2 months prior
             to study start.

          -  Presence of another neoplastic lesion or brain metastases.

          -  Prior hypophysectomy or adrenalectomy.

          -  Known or suspicion of vertebral metastases with risk of spinal compression.

          -  Severe kidney or liver failure (creatinine &gt; 2 x upper limit of normal (ULN),
             aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) &gt; 3 x ULN).

          -  Any concomitant disorder or resulting therapy that is likely to interfere with
             patient compliance or with the study in the opinion of the Investigator.

          -  Participation in another study with an experimental drug within 3 months before study
             start or within 5 drug half-lives of the investigational drug (whichever is the
             longer).

          -  Known hypersensitivity to any of the test materials or related compounds.

          -  Known active use of recreational drug or alcohol dependence in the opinion of the
             Investigator.

          -  Any current use or use within 6 months prior to treatment start of medications which
             are known to affect the metabolism and/or secretion of androgenic hormones:
             ketoconazole, aminoglutethimide, oestrogens, progesterone, and anti-androgens.

          -  Use of systemic or inhaled corticosteroids (topical application permitted).

          -  Inability to give informed consent or to comply fully with the protocol.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eija Lundstrom, MD</last_name>
    <role>Study Director</role>
    <affiliation>Debiopharm SA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johann C. M. Bahlmann, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Richard Barnes, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>New Grootte Schuur Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MC Bigalke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vergelegen Medi-Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>TJ Botha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinresco Centres (Pty) Ltd</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lance Coetzee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pretoria Urology Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>T. Madlala, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>East Rand Urology Research Unit, Clinix Private Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>E Moshokoa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Trial Unit, Room 2-54, Prinshof Medical Campus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>SG Smit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Urology, Tygerberg Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>E Strasheim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Paarl Medical Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cle Van Der Walt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Suite 207, Wilmed Park Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wilmed Park Hospital</name>
      <address>
        <city>Klerksdorp</city>
        <state>North West Province</state>
        <zip>2571</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Grootte Schuur Hospital, Division of Urology</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vergelegen Medi-Clinic</name>
      <address>
        <city>Cape Town</city>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Tygerberg Hospital</name>
      <address>
        <city>Cape Town</city>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paarl Medical Centre</name>
      <address>
        <city>Cape Town</city>
        <zip>7646</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr JCM Bahlmann</name>
      <address>
        <city>Eastern Cape</city>
        <zip>6530,</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Unit, Room 2-54, Prinshof Medical Campus</name>
      <address>
        <city>Gauteng</city>
        <zip>0002</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinresco Centres (Pty) Ltd</name>
      <address>
        <city>Gauteng</city>
        <zip>1619</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pretoria Urology Hospital</name>
      <address>
        <city>Gauteng</city>
        <zip>0083</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Rand Urology Research Unit, Clinix Private Clinic</name>
      <address>
        <city>Johannesburg</city>
        <zip>1475</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <link>
    <url>http://www.debiopharm.com</url>
    <description>Company website</description>
  </link>
  <reference>
    <citation>Klippel KF, Winkler CJ, Jocham D, Rübben H, Möser B, Gulati A. [Effectiveness and tolerance of 1 dosage forms (subcutaneous and intramuscular) of decapeptyl depot in patients with advanced prostate carcinoma]. Urologe A. 1999 May;38(3):270-5. German.</citation>
    <PMID>10407987</PMID>
  </reference>
  <reference>
    <citation>Tornøe CW, Agersø H, Senderovitz T, Nielsen HA, Madsen H, Karlsson MO, Jonsson EN. Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic-pituitary-gonadal axis following treatment with GnRH analogues. Br J Clin Pharmacol. 2007 Jun;63(6):648-64. Epub 2006 Nov 10.</citation>
    <PMID>17096678</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 31, 2014</lastchanged_date>
  <firstreceived_date>July 31, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Triptorelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
